Patents by Inventor Toshikazu Oki

Toshikazu Oki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9138410
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 22, 2015
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Publication number: 20130287852
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 31, 2013
    Inventors: Toshikazu OKI, Takashi HANAFUSA, Shunji HARUTA
  • Patent number: 8435554
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: May 7, 2013
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Patent number: 7732582
    Abstract: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: June 8, 2010
    Assignee: FUJIFILM Corporation
    Inventors: Toshikazu Oki, Yasuhiro Igarashi, Tamotsu Furumai
  • Patent number: 7638138
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: December 29, 2009
    Assignee: Translational Research, Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Publication number: 20090169640
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Application
    Filed: December 30, 2008
    Publication date: July 2, 2009
    Applicant: Translational Research, Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Publication number: 20080299493
    Abstract: An apparatus according to the present invention includes a vacuum chamber (5) and processes a substrate (4) in the vacuum chamber (5). The apparatus includes pumps (8A, 8B; 9A, 9B) which exhaust the vacuum chamber (5), a first cryopump (7A) accommodated in the vacuum chamber (5), a second cryopump (7B) accommodated in the vacuum chamber (5), and a controller (15) which alternatively stops the first cryopump (7A) and the second cryopump (7B).
    Type: Application
    Filed: May 20, 2008
    Publication date: December 4, 2008
    Applicant: CANON KABUSHIKI KAISHA
    Inventor: Toshikazu Oki
  • Publication number: 20080027144
    Abstract: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.
    Type: Application
    Filed: September 5, 2005
    Publication date: January 31, 2008
    Applicant: FujiFilm Corporation
    Inventors: Toshikazu Oki, Yasuhiro Igarashi, Tamotsu Furumai
  • Publication number: 20060233715
    Abstract: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.
    Type: Application
    Filed: February 21, 2003
    Publication date: October 19, 2006
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Publication number: 20050158250
    Abstract: Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.
    Type: Application
    Filed: March 14, 2005
    Publication date: July 21, 2005
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Patent number: 6906027
    Abstract: Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: June 14, 2005
    Assignee: Translational Research Ltd.
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Publication number: 20040063615
    Abstract: Provided is an insulin-containing granulated composition for nasal administration comprising a crystalline cellulose aggregate having a specific particle diameter distribution as a carrier. Such granulated composition for nasal administration can efficiently increase a blood insulin concentration.
    Type: Application
    Filed: July 9, 2003
    Publication date: April 1, 2004
    Inventors: Toshikazu Oki, Takashi Hanafusa, Shunji Haruta
  • Patent number: 5843908
    Abstract: The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.
    Type: Grant
    Filed: September 28, 1990
    Date of Patent: December 1, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Kyoichiro Saitoh, Masami Hatori, Takeo Miyaki, Toshikazu Oki, Koji Tomita
  • Patent number: 5837828
    Abstract: The present invention concerns neutral sugar derivatives of pradimicins, their use as antifungal agents, methods for their preparation, and intermediates for their synthesis.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: November 17, 1998
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Shimpei Aburaki, Tetsuro Yamasaki, Toshikazu Oki, Seiji Iimura, Hajime Kamachi, Hideo Kamei, Takayuki Naito
  • Patent number: 5410029
    Abstract: The present invention concerns neutral sugar derivatives of pradimicins, their use as antifungal agents, methods for their preparation, and intermediates for their synthesis.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: April 25, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shimpei Aburaki, Tetsuro Yamasaki, Toshikazu Oki, Seiji Iimura, Hajime Kamachi, Hideo Kamei, Takayuki Naito
  • Patent number: 5286649
    Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: February 15, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5270196
    Abstract: The present invention relates to an arylsulfatase of microbial origin. The enzyme may be linked to an antibody against a tumor-associated antigen and the resulting conjugate used in conjuction with a sulfated prodrug of a 4'-demethylepipodophyllotoxin glucoside derivative, particularly etoposide in cancer chemotherapy.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: December 14, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Tomokazu Ueki, Satoshi Yamamoto, Koji Tomita, Yasuo Fukagawa, Toshikazu Oki
  • Patent number: 5266600
    Abstract: The present invention provides BU-4641V of the formula: ##STR1## This invention also provides a biologically pure culture of BU-4641V producing Arthrinium sp. FA1744. Another aspect of the invention provides a process for preparing BU-4641V. Yet further aspect of the present invention provides a method for treating mammalian tumors and bacterial or viral infections.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: November 30, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Osamu Tenmyo, Yosuke Sawada, Toshikazu Oki, Masahisa Oka, Masaru Sugawara, Noriyuki Ohkusa
  • Patent number: 5217877
    Abstract: The present invention relates to a novel .alpha.-glucosidase inhibitor, pradimicin Q, having the following formula ##STR1## and its pharmaceutically acceptable base salts.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: June 8, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Tomokazu Ueki, Takashi Tsuno, Toshikazu Oki
  • Patent number: 5183808
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: February 2, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki